Masitinib Inhibits Hepatitis A Virus Replication
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119708 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Reina Sasaki-Tanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 1…. Hauptthemen laut MEDLINE: Hepatitis A, Hepatitis A virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Platform Project for Supporting Drug Discovery and Life Science Research.
Abstract (Originalsprache)
The hepatitis A virus (HAV) infection causes acute hepatitis. HAV also induces acute liver failure or acute-on-chronic liver failure; however, no potent anti-HAV drugs are currently available in clinical situations. For anti-HAV drug screening, more convenient and useful models that mimic HAV replication are needed. In the present study, we established HuhT7-HAV/Luc cells, which are HuhT7 cells stably expressing the HAV HM175-18f genotype IB subgenomic replicon RNA harboring the firefly luciferase gene. This system was made by using a PiggyBac-based gene transfer system that introduces nonviral transposon DNA into mammalian cells. Then, we investigated whether 1134 US Food and Drug Administration (FDA)-approved drugs exhibited in vitro anti-HAV activity. We further demonstrated that treatment with tyrosine kinase inhibitor masitinib significantly reduced both HAV HM175-18f genotype IB replication and HAV HA11-1299 genotype IIIA replication. Masitinib also significantly inhibited HAV HM175 internal ribosomal entry-site (IRES) activity. In conclusion, HuhT7-HAV/Luc cells are adequate for anti-HAV drug screening, and masitinib may be useful for the treatment of severe HAV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan.
- Division of Experimental Animal Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
- Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329-0498, Japan.
ORCID-Profile: Reina Sasaki-Tanaka, Mitsuhiko Moriyama, Hirofumi Kogure, Hiroaki Okamoto, Tatsuo Kanda
Förderung
- Japan Agency for Medical Research and Development
- Platform Project for Supporting Drug Discovery and Life Science Research
Zitieren
APA
Sasaki-Tanaka, R., Shibata, T., Moriyama, M., Kogure, H., Hirai-Yuki, A., Okamoto, H., & Kanda, T. (2023). Masitinib Inhibits Hepatitis A Virus Replication. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119708
Vancouver
Sasaki-Tanaka R, Shibata T, Moriyama M, Kogure H, Hirai-Yuki A, Okamoto H, et al. Masitinib Inhibits Hepatitis A Virus Replication. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119708
BibTeX
@article{SasakiTanaka2023,
author = {Sasaki-Tanaka, Reina and Shibata, Toshikatsu and Moriyama, Mitsuhiko and Kogure, Hirofumi and Hirai-Yuki, Asuka and Okamoto, Hiroaki and Kanda, Tatsuo},
title = {Masitinib Inhibits Hepatitis A Virus Replication},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119708}
}
EUVIMED